4basecare Hiring Genome Analyst

WE'RE HIRING Genome Analyst

Location: Remote

Employment type: Full time

Job Responsibilities

Next Generation Sequencing (NGS) data analysis and interpretation of variants/mutations in cancer using standard guidelines.

Report generation and collaborate with team lead/expert in analyzing and interpreting NGS analysis data directed towards personalized medicine or predisposition/risk analysis of cancer.

Close interaction with the Genome Analyst team/Bioinformatics Team to complete report generation within the promised turnaround time with the desired quality.

Participate in QAD activities, including writing Standard Operating Procedures and policies.

Curation of data that is essential for smooth and timely analysis and reporting.

New feature development and improvement for clinical whole exome sequencing analysis pipelines to patients with cancer.

Qualificatons Required

Master's degree in Life Sciences (M.Sc).

Minimum 1-2 years of relevant experience in oncology.

Strong communication and critical thinking skills.

Knowledge of Bioinformatics tools and their application in variant analysis.

Proficiency in Excel.

Use of Integrated Genome Viewer.

Send Your CV To Email: careers@4basecare.com

Exciting Opportunity: Genome Analyst

Ready to join the mission #TogetherWeBeatCancer! Bring your expertise to the forefront of oncology innovation. Contribute to NGS data analysis, report generation, and cutting-edge research. Join our dynamic team and make a real impact in the fight against cancer.

Send your CV to careers@4basecare.com

#NowHiring #Genomics #Oncology #CareerOpportunity #4baseCare

Company Information

We Overcame Cancer Together To produce high-quality molecular genetic data, we conduct Next Generation-Sequencing (NGS) based genetic testing on DNA and RNA. Through the analysis of Somatic and Germline variations, doctors are enabled to make tailored therapy recommendations for their cancer patients based on genomic data. Based on the strength of the clinical data, which offers insights into pertinent therapeutic choices (targeted and immunotherapy), clinically important genetic biomarkers are examined and prioritized. Our liquid biopsy panel uses the ctDNA method to extract detailed information from peripheral blood on the biology of the tumor, including its current state and how it responds to treatment.

Our liquid biopsy panel uses the ctDNA method to extract detailed information from peripheral blood on the biology of the tumor, including its current state and how it responds to treatment. In order to deliver the most recent and effective treatment recommendations, our multidisciplinary team of cancer researchers, bioinformaticians, and data scientists uses in-house developed custom algorithms that include intricate mathematical and statistical models for thorough curation and correlation of published scientific findings and clinical research.

Somatic Examinations To find somatic mutations, which may assist find the genomic abnormalities for cancer patients that can be treated clinically, somatic genetic and genomic testing are usually carried out on tumor tissue (FFPE block/Fresh tissue). Our TARGT (Tumor-Associated Drug Response by Genomic Testing) panel of genetic and genomic tests has been shown to be very sensitive and specific in detecting somatic mutations in tumor tissue, even at low frequencies that are responsible for malignancy. Every test in the TARGT portfolio finds genetic variations linked to clinical trials and licensed treatments. Actionable and targetable somatic mutations, such as SNVs, Indels, CNAs, and genomic signatures like Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB), are reported by TARGT testing.

Test for Hereditary Cancer Your chance of developing cancer may be raised by genetic variations, mutations, or abnormalities in your inherited genes. Our next-generation sequencing (NGS)-based Hereditary Cancer genetic test, Germline+, examines 213 genes linked to the DNA damage repair (DDR) and homologous recombination repair (HRR) pathways that are implicated in cancer risk. Genes linked to inherited and family malignancies (breast, ovarian, prostate, pancreatic, etc.) are included in the panel. The identified variations are categorized as pathogenic, likely pathogenic, VUS, likely benign, and benign in accordance with ACMG standards. This could indicate a low, moderate, or high risk of developing cancer. Certain germline variations, such as those in the BRCA gene, aid in both determining cancer risk and guiding treatment choices using PARP (Poly-ADP-Ribose Polymerase) inhibitor targeted therapy.

Assay for Liquid Biopsy A minimally invasive blood-based test called a liquid biopsy can help cancer patients make decisions about their therapeutic course of therapy as well as diagnosis and prognosis. From peripheral blood, the assay isolates and finds tumor genomes together with related genomic changes such SNVs/InDels, CNAs, and Gene Fusions. It has been acknowledged that liquid biopsies are an important diagnostic and observational technique. Oncologists all around the world are using liquid biopsies for a variety of cancer patients after the FDA approved its use for solid tumors and non-small cell lung cancer. Using the liquid biopsy approach, a patient with cancer has blood drawn, and the tumor's presence or composition is examined in the blood.

Because they just involve taking a patient's blood, liquid biopsies are said to be less invasive than tissue biopsies and are quicker, simpler, and less unpleasant than tissue biopsies. In order to precisely manage cancer, the procedure entails removing tumor DNA from blood and then analysing it using NGS.